PharmaCyte Biotech (PMCB) announced the successful monetization of its stake in Femasys (FEMY). Following the monetization of the stake, PharmaCyte’s cash and marketable securities are expected to increase to approximately $20M, up from $13.3M as of July 31.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMCB: